iPS Cells & Regenerative Medicine– category –
-
FDA Regenerative Medicine Approvals Accelerate, Outpacing Previous Years with Record Potential for 2026
PharmaLive USA Overview FDA approvals for regenerative medicine products are accelerating significantly, with a record eight approvals in 2024. Approvals between 2023 and 2025 more than doubled the total from 2016-2022. As of July 2026, ... -
CRISPR Gene Editing Therapies Limited to Ex Vivo Approvals for Sickle Cell and Beta-Thalassemia in 2026; In Vivo Candidates Show 87% Attack Reduction and 62% Cholesterol Decrease
DeepDNA USA Overview As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, in vivo therapies are demonstrating sign... -
Fate Therapeutics’ iPSC-Derived CAR-T FT819 Shows Safety and Improved Skin Scores in Refractory Systemic Sclerosis Phase 1; Repligen Acquires BioLife Solutions for $1.5 Billion
DeciBio USA Overview July 2026 highlights in next-generation therapeutics include Fate Therapeutics' preliminary Phase 1 data for FT819, an iPSC-derived CD19-targeted CAR-T cell therapy for treatment-refractory systemic sclerosis, demons... -
Washington University Reports Promising Early Results for Aggressive Blood Cancers with Combined CRISPR Gene Editing and Stem Cell Transplant
The Brighter Side of News USA Overview Researchers at Washington University School of Medicine in St. Louis reported promising early results from a clinical trial combining CRISPR gene editing with stem cell transplantation to treat aggr... -
NueCell Bio Launches as Translational Partner to Accelerate Cell Therapies from Discovery to GMP Manufacturing
PR Newswire USA Overview NueCell Bio has officially launched as a new "translational partner" dedicated to accelerating cell therapy products from scientific discovery through GMP-compliant manufacturing and clinical readiness. The compa... -
Opus Genetics Completes Patient Enrollment in Phase III Trial of Gene Therapy for Inherited Retinal Dystrophy
Precision Medicine Online USA Overview Opus Genetics has completed patient enrollment in its Phase III clinical trial for a gene therapy targeting severe inherited retinal dystrophy. This milestone signifies a critical step towards poten... -
Vertex’s CASGEVY Gene Therapy Expands FDA Approval to Pediatric Patients 2+ for Sickle Cell and Beta-Thalassemia; Umoja’s In Vivo CAR-T for Solid Tumors Enters Clinic
BioInsights USA Overview July 2026 marked significant progress in gene and cell therapy access, with Vertex Pharmaceuticals' CASGEVY receiving expanded FDA approval for pediatric patients aged 2 and older with sickle cell disease and tra... -
Umoja Biopharma Initiates Phase 1/2 Trials for In Vivo CAR-T Therapies UB-VV400 and UB-VV500 Targeting B-Cell Malignancies and Multiple Myeloma
Gene Therapy Net (ClinicalTrials.gov) USA Overview Umoja Biopharma is set to initiate Phase 1/2 clinical trials for its investigational in vivo CAR-T cell therapies, UB-VV400 for recurrent/refractory B-cell malignancies and UB-VV500 for ... -
FDA Issues Warnings as No Approved Therapeutic Exosomes Exist in 2026 Amidst Reports of Adverse Events
OmniGenix USA Overview As of 2026, the U.S. FDA has not approved any therapeutic exosome products, issuing warnings against unauthorized sales due to reported adverse events. A 2025 review of clinical trials from 2014-2024 indicated favo... -
iPS Cells & Regenerative Medicine Weekly Report August 2, 2026
📄 Weekly Report August 02, 2026 (PDF) — Download Weekly Report August 02, 2026 (PDF) — DownloadDownload 🎙 Podcast August 02, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260802.mp3Download View Past Weekly Reports→
